SI3068403T1 - Metode zdravljenja okularnih stanj z implantantom za dostavo zdravila s podaljšanim sproščanjem - Google Patents

Metode zdravljenja okularnih stanj z implantantom za dostavo zdravila s podaljšanim sproščanjem

Info

Publication number
SI3068403T1
SI3068403T1 SI201431652T SI201431652T SI3068403T1 SI 3068403 T1 SI3068403 T1 SI 3068403T1 SI 201431652 T SI201431652 T SI 201431652T SI 201431652 T SI201431652 T SI 201431652T SI 3068403 T1 SI3068403 T1 SI 3068403T1
Authority
SI
Slovenia
Prior art keywords
treatment
methods
drug delivery
sustained drug
ocular conditions
Prior art date
Application number
SI201431652T
Other languages
English (en)
Slovenian (sl)
Inventor
Jane-Guo Shiah
Rahul Bhagat
Wendy M. Blanda
Thierry Nivaggioli
Lin Peng
David Chou
David A. Weber
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52001114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3068403(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of SI3068403T1 publication Critical patent/SI3068403T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
SI201431652T 2013-11-15 2014-11-14 Metode zdravljenja okularnih stanj z implantantom za dostavo zdravila s podaljšanim sproščanjem SI3068403T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904887P 2013-11-15 2013-11-15
PCT/US2014/065804 WO2015073895A1 (en) 2013-11-15 2014-11-14 Methods of treatment of ocular conditions with a sustained drug delivery implant
EP14805768.0A EP3068403B2 (en) 2013-11-15 2014-11-14 Methods of treatment of ocular conditions with a sustained drug delivery implant

Publications (1)

Publication Number Publication Date
SI3068403T1 true SI3068403T1 (sl) 2020-11-30

Family

ID=52001114

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201431652T SI3068403T1 (sl) 2013-11-15 2014-11-14 Metode zdravljenja okularnih stanj z implantantom za dostavo zdravila s podaljšanim sproščanjem

Country Status (24)

Country Link
US (2) US20150140062A1 (enExample)
EP (2) EP3068403B2 (enExample)
JP (2) JP6675307B2 (enExample)
KR (3) KR20240058976A (enExample)
CN (1) CN105764517A (enExample)
AU (4) AU2014348369B2 (enExample)
CA (1) CA2929689A1 (enExample)
CL (1) CL2016001167A1 (enExample)
CY (1) CY1123344T1 (enExample)
DK (1) DK3068403T3 (enExample)
ES (1) ES2819215T3 (enExample)
HU (1) HUE050913T2 (enExample)
IL (2) IL245548A0 (enExample)
MX (2) MX2016006334A (enExample)
MY (1) MY176039A (enExample)
NZ (1) NZ719953A (enExample)
PH (1) PH12016500869B1 (enExample)
PL (1) PL3068403T3 (enExample)
PT (1) PT3068403T (enExample)
RU (1) RU2690841C1 (enExample)
SG (1) SG10201809363SA (enExample)
SI (1) SI3068403T1 (enExample)
UA (1) UA122117C2 (enExample)
WO (1) WO2015073895A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6914931B2 (ja) * 2015-07-23 2021-08-04 アエリエ ファーマシューティカルズ インコーポレイテッド 眼の症状の治療のための医薬組成物、硝子体内インプラント及び医薬品の製造におけるそれらの使用
JP2019534063A (ja) 2016-09-02 2019-11-28 エンビシャ セラピューティクス インコーポレイテッド インプラントアプリケータ
CN111971026A (zh) 2018-05-24 2020-11-20 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
BR112020023982A2 (pt) 2018-05-24 2021-02-23 Celanese Eva Performance Polymers Llc dispositivo implantável para liberação prolongada de um composto de fármaco macromolecular
KR20230041708A (ko) * 2020-07-16 2023-03-24 오큘라 테라퓨틱스, 인코포레이티드 글루코코르티코이드를 함유하는 안구 삽입물
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AU3649502A (en) 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
WO2012109673A1 (en) * 2011-02-11 2012-08-16 Psivida Us, Inc. Methods of treating macular edema using antiedema therapeutics

Also Published As

Publication number Publication date
UA122117C2 (uk) 2020-09-25
US20250319031A1 (en) 2025-10-16
CL2016001167A1 (es) 2017-01-06
IL245548A0 (en) 2016-06-30
NZ719953A (en) 2022-01-28
SG10201809363SA (en) 2018-11-29
MX2016006334A (es) 2016-09-06
KR20240058976A (ko) 2024-05-07
KR20220082934A (ko) 2022-06-17
AU2022204607A1 (en) 2022-07-21
PT3068403T (pt) 2020-09-18
CA2929689A1 (en) 2015-05-21
US20150140062A1 (en) 2015-05-21
CN105764517A (zh) 2016-07-13
KR20160085847A (ko) 2016-07-18
ES2819215T3 (es) 2021-04-15
PH12016500869A1 (en) 2016-07-04
JP7022735B2 (ja) 2022-02-18
MY176039A (en) 2020-07-22
CY1123344T1 (el) 2021-12-31
PL3068403T3 (pl) 2021-01-11
AU2024205640B2 (en) 2025-10-23
RU2016119132A (ru) 2017-12-20
HUE050913T2 (hu) 2021-01-28
AU2020204362A1 (en) 2020-07-23
AU2024205640A1 (en) 2024-08-29
EP3068403B1 (en) 2020-06-17
DK3068403T3 (da) 2020-09-07
RU2690841C1 (ru) 2019-06-06
EP3068403A1 (en) 2016-09-21
IL290837A (en) 2022-04-01
AU2014348369A1 (en) 2016-06-09
KR102475746B1 (ko) 2022-12-08
WO2015073895A1 (en) 2015-05-21
EP3714875A1 (en) 2020-09-30
MX2022002306A (es) 2022-03-25
PH12016500869B1 (en) 2016-07-04
AU2014348369B2 (en) 2020-04-02
JP6675307B2 (ja) 2020-04-01
JP2020055862A (ja) 2020-04-09
EP3068403B2 (en) 2025-12-03
JP2016538292A (ja) 2016-12-08

Similar Documents

Publication Publication Date Title
IL290837A (en) Methods for the treatment of ocular diseases using a continuous drug delivery implant
IL244259A0 (en) Insertion of medical devices
EP2838511A4 (en) OCULAR MEDICATION DELIVERY SYSTEM
ZA201405898B (en) Devices for targeted delivery of therapeutic implants
PT2648663E (pt) Dispositivo para administração por iontoforese de riboflavina na córnea para o tratamento de queratocone
IL240849B (en) Drug delivery devices and drug delivery method
HUE072250T2 (hu) Gyógyszeradagoló eszközök gyógyszeráteresztõ résszel
EP2768430A4 (en) CORNEAL IMPLANT STORAGE AND INSTALLATION DEVICES
EP2908874A4 (en) MEDICAL ACTIVE COMPOSITION DEVICE
SG11201502274XA (en) A device for a medical treatment of a sclera
EP3183026A4 (en) Implants for localized drug delivery and methods of use thereof
PL3073936T3 (pl) Wszczep medyczny
IL262062A (en) Implantable ophthalmic drug delivery devices
PL3413872T3 (pl) Nieinwazyjna wkładkowa technologia podawania leków do oka
EP2893903A4 (en) IMPLANTABLE DEVICE FOR MOLDING THE CORD BEND
IL242760B (en) A Biomimetic Peptide and Biodegradable Delivery Platform for the Treatment of Angiogenesis and Lymphangiogenesis-Dependent Diseases
HUE046600T2 (hu) Biológiailag lebomló ötvözeteket tartalmazó beültethetõ gyógyászati eszközök javított lebomlási sebességgel
ZA201403767B (en) Implantable drug delivery compositions and methods of treatment
PT2959903T (pt) Medicamento para tratar doença ocular
IL232460A0 (en) A biologically compatible implantable electorada
GB201721832D0 (en) Ocular drug delivery
PL2556806T3 (pl) Wszczepialna proteza medyczna
GB201316738D0 (en) Implantable Medical Devices
GB201319437D0 (en) Delivery of drugs
IL245983B (en) Biologically active insulin derivatives